Skip to main content
. 2015 Jun;87(6):1006–1012. doi: 10.1124/mol.114.097477

Fig. 3.

Fig. 3.

Effects of HIF siRNA and enzalutamide on AR transcriptional activation. LNCaP cells were treated with 20 nM HIF-1α siRNA (siHIF-1α) or control siRNA (siControl) for 48 hours. Cells were incubated in normoxia (N) or CoCl2 for an additional 18 hours. HIF-1α siRNA repressed HIF (A) and VEGF (B) transcripts. (C) After siRNA treatment, cells were transfected with pARE-Luc and pRL-TK for 24 hours followed by treatment with enzalutamide in the presence and absence of 1 nM DHT in normoxia or hypoxia for an additional 18 hours. Luciferase activities were determined, and data are expressed as means ± S.E.M. (n = 3). HIF-1α siRNA and enzalutamide repressed ARE luciferase activation (P ≤ 0.034), whereas combined HIF-1α siRNA and enzalutamide treatment was more effective than either treatment alone (P ≤ 0.010). (D) HIF siRNA and enzalutamide repressed ARE-luc activation in 22Rv1 cells (P < 0.001), and enzalutamide treatment was more effective than either treatment alone (P < 0.001). *P < 0.05; **P ≤ 0.01; ***P < 0.001.